1. COVID-19 in Liver Transplant Candidates: Pre- and Post-Transplant Outcome
- Author
-
Giovanni P, Hann A, Invernzzi F, lesurtel m, G. Magini, François Faitot, C. Morelli, Stefano Fagiuoli, Karam, Damiano Patrono, Renato Romagnoli, Diaz-Fontenla F, Kounis I, C. Fondevila, zieniewicz k, Rita Facchetti, Paolo Cortesi, Paolo De Simone, Elkrief L, Mirza D, Iacob S, Caroline M. den Hoed, Gheorghe L, Sylvie Radenne, Bo Göran Ericzon, Marco Merli, Lluis Castells, Carmelo Loinaz, Christophe Duvoux, Roberto Fumagalli, Berlakovic G, Sara Conti, Christian Toso, Perera T, Luca S. Belli, Wojciech G. Polak, Massimo Puoti, Luciano Dc, Kollmann D, Detry O, Luisa Pasulo, and Audrey Coilly
- Subjects
medicine.medical_specialty ,education.field_of_study ,Cirrhosis ,business.industry ,Proportional hazards model ,medicine.medical_treatment ,Population ,Liver transplantation ,medicine.disease ,Vaccination ,Respiratory failure ,Internal medicine ,medicine ,media_common.cataloged_instance ,European union ,business ,education ,media_common ,Cause of death - Abstract
Background: The impact of COVID-19 on patients on the waiting list for liver transplantation (LT) and on their post-LT course is presently unknown. Methods: Data from consecutive adult LT candidates with COVID-19 were collected across Europe in a dedicated registry and analyzed. Findings: From February 21st to November 20th, 2020, 136 adult cases with laboratory confirmed SARS-CoV-2 infection from 33 centers in 11 European countries were collected, with 113 having COVID-19. Thirty-seven (37/113, 32·7%) patients died after a median of 18 (10-30) days, respiratory failure being the major cause (33/37, 89·2%). The 60-day mortality risk did not significantly change between first (35·3%, 95% CI 23·9-50·0) and second wave (26·0%, 95% CI 16·2-40·2). Multivariable Cox regression analysis showed lab-MELD score ≥15 (MELD 15-19 HR 6·09, 95% CI 2·01-18·45; MELD ≥20 HR 5·21, 95% CI 1·76-15·45) and dyspnea on presentation (HR 4·10, 95% CI 2·09-8·06) being the two negative independent factors for mortality. The mortality risk reached 49·2% (31/63) in patients with decompensated cirrhosis and lab-MELD score ≥15. Twenty-six patient received a LT after a median time of 78.5 (IQR 44-102) days and 25 (96%) are alive after median follow-up of 118 days (IQR 31-170). Interpretation: Increased mortality in LT candidates with COVID-19 (32·7%), reaching 49·2% in those with decompensated cirrhosis and lab-MELD score ≥15, with no significant difference between first and second wave of the pandemic. Respiratory failure was the major cause of death. The dismal prognosis of patients with decompensated cirrhosis supports the adoption of strict preventative measures and the urgent testing of vaccination efficacy in this population. Prior SARS-CoV-2 symptomatic infection did not affect early post-transplant survival (96%). Funding: No funding source. Declaration of Interests: None to declare. Ethics Approval Statement: Data was collected in accordance with General Data Protection Regulation (GDPR), the European Union legislation and the ELTR privacy policy. Reg. HCB/2020/0479 released by CLINICAL RESEARCH ETHICS COMMITTEE from Hospital Clinic Barcelona
- Published
- 2021